Rinkey Investments’s Enveric Biosciences ENVB Stock Holding History

Rinkey Investments’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	-$5K	–	98
2021 Q4	$5K	Buy	+1	New	+$14.1K	﹤0.01%	191

Other funds holding ENVB

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rinkey Investments's ENVB Position: Q1 2022 in Review

Rinkey Investments sold out of Enveric Biosciences (ENVB) in Q1 2022, closing a stake of 1 share — an estimated $5K sold.

Rinkey Investments first reported a position in ENVB in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 26 funds tracked by Wall St. Rank hold ENVB as of Q1 2022.

Rinkey Investments reported no remaining Enveric Biosciences position as of Q1 2022 after selling out during the quarter.
Rinkey Investments sold 1 Enveric Biosciences share in Q1 2022, an estimated $5K.
Rinkey Investments first reported a position in Enveric Biosciences in Q4 2021 and held it in 1 quarter.
Rinkey Investments's Enveric Biosciences position peaked at $5K in Q4 2021.
26 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2022.

Based on Rinkey Investments's 13F filing for Q1 2022, filed 9 May 2022.